Britex

An antiglaucoma combination drug containing two active substances: brimonidine, a selective alpha-2 adrenergic receptor agonist, and timolol, a non-selective beta-blocker. Both active substances reduce IOP through a combined interaction, leading to a significantly more pronounced hypotensive effect compared to the effect of each component separately.

• Brimonidine BP tartrate 0.2% w/v;
• Timolol maleate USP eq. timolol 0.5% w/v;
• Benzalkonium chloride solution NF 0.01% w/v (as a preservative);
• Sterile aqueous base qs.

• open-angle glaucoma;
• ocular hypertension (with insufficient effectiveness of local therapy with beta-blockers).